Skip to main content

Table 2 Summary of the planning objectives and average results (uncertainty expressed as 1 standard deviation) for the clinical target volume (CTV) and for the planning target volume (PTV)

From: Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin’s lymphoma. Assessment of risk of toxicity and secondary cancer induction

Parameter

Objective

RA

IMPT

p

CTV

 Volume: 303 ± 226 Range: [50–927] cm3

  Mean [Gy]

30

30.0 ± 0.0

30.0 ± 0.0

 

  D95% [Gy]

> 29.4 (98%)

29.6 ± 0.1

29.6 ± 0.1

0.3

  D98% [Gy]

> 25.5 (95%)

29.4 ± 0.1

29.4 ± 0.2

0.5

  D1% [Gy]

< 32.1 (107%)

30.9 ± 0.2

31.0 ± 0.2

0.1

  St. Dev [Gy]

Minimize

0.3 ± 0.1

0.4 ± 0.1

0.01

  HI

Minimize

0.04 ± 0.01

0.05 ± 0.01

0.1

PTV

 Volume: 639 ± 370 Range: [117–1456] cm3

  Mean [Gy]

30

29.9 ± 0.1

29.9 ± 0.1

0.3

  D95% [Gy]

> 28.5 (95%)

28.7 ± 0.3

28.8 ± .03

0.2

  D98% [Gy]

> 27.0 (90%)

28.0 ± 0.4

28.1 ± .04

0.5

  D2% [Gy]

< 32.1 (107%)

31.1 ± 0.2

31.4 ± 0.3

0.01

  St. Dev [Gy]

Minimize

0.6 ± 0.1

0.7 ± 0.2

0.08

  HI

Minimize

0.07 ± 0.02

0.06 ± 0.01

0.07

  1. RA RapidArc, IMPT Intensity modulated proton therapy, Dx% dose received by at least (maximum) x% of the volume, HI (D5-D95)/Dmean